1.	Phase II/III Randomized Study of High-Dose vs Moderate-Dose LGD1069 vs Placebo in Advanced non-Small Cell Lung Cancer (Summary Last Modified 08/98) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-20, NCI-V96-1050
2.	Phase II/III Study of Targretin (LGD1069) Capsules in Patients with Refractory or Recurrent Early Stage T-Cell Lymphomas (Summary Last Modified 05/1999) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-23, NCI-V97-1149
3.	Phase II/III Evaluation of Targretin Capsules in Patients with Refractory Advanced Stage Cutaneous T-Cell Lymphoma (Summary Last Modified 11/98) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-24, NCI-V97-1151
4.	Phase III Study of Targretin (LGD1069) Topical Gel in Patients with Refractory or Persistent Early Stage Cutaneous T-Cell Lymphoma (Summary Last Modified 12/98) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069T-25, NCI-V97-1292
5.	Phase III Randomized Study of Cisplatin and Vinorelbine With or Without Bexarotene in Patients With Chemotherapy-Naive Advanced or Metastatic Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-49
6.	Phase III Randomized Study of Carboplatin and Paclitaxel With Bexarotene Versus Carboplatin and Paclitaxel Alone in Patients With Chemotherapy-Naive Stage IIIB or IV Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-48, BMC-C-7093-49, UCLA-0301086
7.	Phase I/II Pilot Study of Topical LGD1069 (a Selective Retinoid) for Cutaneous T-Cell Lymphoma (Summary Last Modified 09/98) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: Other Protocol IDs: MDA-DM-94098, NCI-V95-0621
8.	Phase I/II Multicenter Study of Combination Therapy With LGD1069 Oral Capsules (Targretin) and Interferon Alfa-2b (Intron A) in Patients With Advanced Renal Cell Carcinoma (Summary Last Modified 12/98) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UCLA-HSPC-960630001, LIGAND-L1069-17, LIGAND-UCLA-HSPC-960630001, NCI-V97-1205
9.	Phase II Study of Oral LGD1069 plus IFN-A for Metastatic Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: YALE-HIC-8644, LIGAND-YALE-HIC-8644, NCI-V96-0882
10.	Phase II Study of Oral LGD1069 (a Synthetic Retinoid Analogue) for AIDS-Related Kaposi's Sarcoma (Summary Last Modified 07/98) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-21, NCI-V96-0973
11.	Phase II Study of Targretin (LGD1069) Capsules in Metastatic Androgen Independant Prostate Cancer (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-22, NCI-V97-1124
12.	A Multicenter Phase II Evaluation of Targretin Capsules (LGD 1069) in Asymtomatic Patients with Ovarian Cancer Now with an Elevated Serum CA 125 Following Complete Remission (Summary Last Modified 12/98) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MSKCC-96061, LIGAND-MSKCC-96061, NCI-G97-1140
13.	Phase II Randomized Study of Bexarotene (LGD1069) in Patients with Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: LIGAND-L1069-34, MSKCC-99008, UMN-9808M00110, NCT00003752
14.	Phase II Randomized Study of Bexarotene and Ultraviolet A Light Therapy With Methoxsalen (PUVA) in Patients With Stage IB or IIA Cutaneous T-Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MILL-61896, LIGAND-MILL-61896, NU-IRB-837-002, NCT00030589
15.	Phase II Study of Bexarotene and Interferon alfa in Patients With Cutaneous T-Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-01128, NCI-G01-2049, NCT00030849
16.	Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: D-0440, NCT00125359
17.	Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 050416, NCT00178841
18.	Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000454838, MSKCC-05098, NCT00255801
19.	Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000525989, P30CA006973, JHOC-J0675, JHOC-NA_00003076, J0675, NCT00425477
20.	BATTLE Program: Tarceva and Targretin in Patients With NSCLC Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2005-0826, NCT00411632
21.	Phase I Study of Daily Oral LGD1069 for Advanced, Recurrent Squamous Cell Cancer of the Head and Neck (Summary Last Modified 06/98) Phase: Phase I Type: Treatment Status: Completed Age: over 18 Sponsor: Other Protocol IDs: MDA-DM-94045, NCI-V94-0497
22.	Study of Bexarotene in Patients With Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: UPCC 12403, 708935, NCT00316030
23.	Randomized Chemoprevention Study of Bexarotene in Women at High Genetic Risk for Breast Cancer Phase: No phase specified Type: Prevention Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: BCM-H-9315, U19-CA-86809-2, NCT00055991
24.	Study of Tarceva and Targretin in Stage I-II Lung Cancer Phase: No phase specified Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: D-0453, NCT00125372